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Abstract: A fracture that does not unite in nine months is defined as nonunion. Nonunion is common in fragmented fractures and large
bone defects where vascularization is impaired. The distal third of the tibia, the scaphoid bone or the talus fractures are furthermore prone
to nonunion. Open fractures and spinal fusion cases also need special monitoring for healing. Bone tissue regeneration can be attained
by autografts, allografts, xenografts and synthetic materials, however their limited availability and the increased surgical time as well as
the donor site morbidity of autograft use, and lower probability of success, increased costs and disease transmission and immunological
reaction probability of allografts oblige us to find better solutions and new grafts to overcome the cons. A proper biomaterial for
regeneration should be osteoinductive, osteoconductive, biocompatible and mechanically suitable. Cytokine therapy, where growth
factors are introduced either exogenously or triggered endogenously, is one of the commonly used method in bone tissue engineering.
Transforming growth factor β (TGFβ) superfamily, which can be divided structurally into two groups as bone morphogenetic proteins
(BMPs), growth differentiation factors (GDFs) and TGFβ, activin, Nodal branch, Mullerian hormone, are known to be produced by
osteoblasts and other bone cells and present already in bone matrix abundantly, to take roles in bone homeostasis. BMP family, as the
biggest subfamily of TGFβ superfamily, is also reported to be the most effective growth factors in bone and development, which makes
them one of the most popular cytokines used in bone regeneration. Complications depending on the excess use of growth factors, and
pleiotropic functions of BMPs are however the main reasons of why they should be approached with care. In this review, the Smad
dependent signaling pathways of TGFβ and BMP families and their relations and the applications in preclinical and clinical studies will
be briefly summarized.
Key words: BMP, TGFβ, bone regeneration, release, signaling, cytokine

1. Introduction
Trauma, tumor resection, degeneration, deformation
may cause bone defects in which the healing process is
controlled by cytokines as bone morphogenetic proteins
(BMP) or transforming growth factor beta (TGFβ), are a
great challenge for regeneration studies [1,2,3,4]. Bone loss
is frequently difficult to reconstruct due to limitations in
autografts, allografts, natural or synthetic composites [1].
In 2015 Sheikh et al. [5] mentioned that about 5% to 10%
of all the procedures related with impaired healing are due
to physiological stress and they cause morbidity in patients
while a significant economic loss is recorded. Every year at
least 6.3 million people are reported to suffer from bone
fractures in the US as reported by the AAOS and 25% of
these cases require bone grafting [5]. Autografts, standard
in treatment of bone defects, are the most commonly used
grafts because of their osteoinductivity, osteoconductivity

and being nonimmunogenic; however, they have
disadvantages as increased surgical time and donor site
morbidity [1,2,4,6,7]. On the other hand, allografts are
also osteoconductive and slightly osteoinductive and do
not have complications as donor site morbidity but have
the probability of disease transmission or rejection by the
immune system and their bone repair capability is half of
the autografts, with higher price [1,4,8,9]. Together with
these disadvantages, the collected tissue for regeneration
may not always be sufficient enough to fill the defect
[10,11]. In order to overcome these constrictions, synthetic
materials and composites became a popular research area
in tissue engineering field.
An optimal graft should be osteoinductive,
osteoconductive,
nonimmunogenic,
biocompatible,
mechanically compatible and depending on the
application area and purpose, it may be biodegradable or
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nonbiodegradable [11,12]. The new generation of smart
materials are aimed to achieve bone regeneration with the
lowest possible use of cytokines in order to decrease the side
effects of these growth factors [13]. Success of the implant
also depends on the induction of migration capability of
cells to implant area and in the presence of BMP, BMSCs
are reported to migrate to the regeneration area [14]. In
the process of regeneration, cell migration to damaged
areas, angiogenesis, fibrosis, chemokine secretions and
differentiation of stem cells are especially important [15].
Thus, osteogenic growth factors or cytokines are generally
used in bone tissue engineering due to their osteoinductive
abilities because they are able to attract the progenitor
cells to the defect area and promote the cell proliferation,
migration and endogenous repair mechanisms [1,10].
Their effects on the mechanism of bone regeneration via
migration, proliferation, differentiation and reconstruction
of the extracellular matrix are in time dependent manner
[1,4].
Throughout these cytokines, bone morphogenetic
proteins (BMPs), as being the biggest subfamily of TGFβ
superfamily, are the most commonly used growth factors
because they are already present in bone tissue and
reported to be necessary for fetal tissue development and
fracture repair [1,2,4,6,10,16]. TGFβ, itself, is also known
as an important growth factor in regulation of osteoblast
and osteoclast activities which is an important process for
bone homeostasis and remodeling [17,18].
The use of BMP-2 in spine for anterior lumbar
spinal fusion has approved by FDA (US Food and Drug
Administration), yet the excess amount of BMP, leakage or
uncontrolled burst release can cause inflammation, edema,
nerve root compression and seroma formation, radiculitis,
ectopic bone formation, immune response, osteolysis,

cervical and soft tissue edema, osteoclast mediated bone
resorption, wound complications, urogenital disorders,
inappropriate adipogenesis and heterotrophic bone
formation [1,2,11,19,20]. Although BMPs are known as key
factors in the commitment of stem cells to osteoprogenitor
lineage, especially in the spinal applications, the excess
amount of BMP is reported to cause cancer [11]. Effects of
BMPs on growing tissues are also unclear, so while using
BMPs during childhood, adolescence and pregnancy
extreme care should be taken and its use in patients with
tumor and active infections or pregnancy is reported to be
contraindicated [1,21].
2. TGFβ superfamily
IGFβ, TGFβ and BMP families are subfamilies of TGFβ
superfamily. TGFβ superfamily members are known to
be produced by osteoblasts (OB) and other bone cells and
they are found in bone matrix abundantly [22–24]. They
are also known to stimulate osteoblast proliferation and
differentiation in vitro, bone formation when externally
administrated in vivo, and cell migration-survivaldifferentiation, osteoprogenitor proliferation, early
differentiation, osteoblastic lineage commitment through
noncanonical MAPK and canonical Smad pathways [18,
23–27]. TGFβ family structurally can be divided into two
as, BMPs together with GDFs which have a rigid butterfly
confirmation and activins, Nodal branch, anti-Mullerian
hormone, Myostatin with TGFβ which possess a level of
flexibility [22, 28, 29] (Figure 1).
In cell signaling, TGFβ signals are conveyed through 2
types of serine-threonine kinase transmembrane receptors,
as type II and type I Receptors, to Smad molecules, which
are intracellular mediators of this signaling pathway or in
other words they are mostly “one-way buses” of the TGFβ

TGFβ
(Structurally)

BMPs
GDFs
Extended

TGFβ
Nodal branch
h TGFβ
Posses a level
of

Figure 1. TGFβ superfamily members.
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signaling pathway that carry signals between nucleus and
cytoplasm and this signaling system is highly conserved
through evolution [22, 25–33]. The signaling system
that uses these one-way Smad buses are known as Smad
dependent or canonical TGFβ signaling system [26,27,29].
The other pathway is known as non-Smad pathway which
includes p38 - MAPK, Rho - like GTPase signaling and
PI3K/AKT pathways [27,28]. As an example of how
noncanonical TGFβ pathways works; TGFβ can promote
osteoprogenitor proliferation and osteoblastic lineage
commitment via MAPK-Smad2/3, also TGFβ2 can induce
the activation of ERK-MAPK and can promote osteoblastic
differentiation via stimulating cell proliferation; or via
MAPK pathways BMP induced OB differentiation can be
induced [26,27,33] (Figure 2).
In the canonical TGFβ pathway, the Smad molecules
are the main intracellular mediators. In mammals, 8
Smad molecules from Smad1 to Smad8 were defined.
They are categorized as (receptor regulated-Smads, the
downstream key molecules for receptors to transduce
signals) R-Smads, (common mediator-Smad) Co-Smad
and (inhibitory-Smads) I-Smads [26, 28, 31, 33, 34– 39]
(Figure 3). Smad 1, Smad 2, Smad 3, Smad 5, Smad 8
are known as R-Smads, Smad 4 is known as Co-Smad,
and Smad 6, Smad 7 are known as I-Smads [28, 29,
32–34]. Briefly, transphosphorylation of type I-R (type
I Receptor) by constitutively active type II-R (type II

TGFβ
β

Receptor) kinase happens via ligand (BMPs or TGFβs)
binding. The activation of type I serine/theronine kinases
(type I-R) initiates the post receptor signaling cascade via
phosphorylation of R-Smads. Phosphorylated R-Smads
forms a complex with Co-Smad and this complex
formation translocates R-Smad/Co-Smad complex to the
nucleus, where they can either integrate with DNA binding
proteins or directly regulate transcriptional activity by
binding to regulatory elements of target genes either as
monomers or in association with Co-Smad [22, 23, 28, 30,
33–35] (Figure 4).
Rahman et al. [28] mentioned that in nucleus Smads
are also able to participate in histone modifications and/
or chromatin remodeling. I-Smads on the other hand,
negatively regulates this signaling process by preventing
the complex formation between R-Smads and Co-Smad
via blocking the phosphorylation of R-Smads [32] or as for
Smad 6, competing with R-Smads for Smad4 (Co-Smad)
binding and forming a nonfunctional complex with Smad4
[26]. Smurfs, as Smurf1 and Smurf2, are also reported to
suppress TGFβ or BMP signaling via degradation of Smads
and receptors for TGFβ and BMP [26].
Although TGFβ contributes to bone regeneration
also via potentiating the osteoinductive activities of BMP,
osteoinductive activity of TGFβ is reported to be much
lower than BMPs [24]. Thus in bone regeneration studies
TGFβ family and especially BMP family are one of the
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Figure 2. Mechanisms of TGFβ on bone.
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Figure 4. Basic mechanism of signal transduction via Smad dependent pathway in
TGFβ family signaling.
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most commonly used growth factors. For this reason, the
focus of this review article is TGFβ and mainly BMP.
2.1. TGFβ family and its signaling
TGFβ, as one of the most abundantly found cytokines
in bone matrix, is produced by osteoblasts and found
merged in mineralized matrix, even in higher amounts
than BMPs [18,24,31,36]. Although its role in osteogenesis
has not been explained clearly yet, it is shown to be
released during bone resorption to recruit bone marrow
mesenchymal stromal/stem cells (BMMSC) to resorption
sites, and to limit the further osteoclast formation
indirectly by reducing the ability of osteoblasts to secrete
RANKL (an osteoclast differentiation factor) and is also
reported to promote matrix production, osteoblastic
differentiation, yet still noted to stimulate bone resorption
by differentiation of osteoclasts [17,18,26,36,37]. During
development, growth and fracture healing, it is highly
expressed in mature osteoblasts and is relevant to skeletal
morphogenesis such as generation of bone shape, bone
growth or bone remodeling since it is also effective in
bone and cartilage formation [17,24,38,39]. TGFβ is
reported to either inhibit or stimulate the osteoblastic cell
proliferation depending on the cell densities, species and
stage of osteoblast differentiation [17,18,24]. Although
TGFβ expression is decreased in human bone with aging,
the level of TGFβ is reported to be elevated in bone from
patients with osteoarthritis [24].
Expression of osteoblastic differentiation markers
such as, ALP, Col I and osteonectin are reported to be
increased under the effect of TGFβ, while osteocalcin
synthesis is reported to be inhibited in human
osteoblasts [24]. In contrast, it is reported to inhibit the
differentiation of osteoblasts in rat osteoblast cultures
and the mineralization via interaction of HDAC4 and
HDAC5 recruitment to Runx2 which is promoted by
Smad3 connection
[24,26,28,36]. Both TGFβ1 and TGFβ2






























  















are, however, shown to promote osteoprogenitor cells into
osteoblasts through non-Smad MAPK pathways or Smad
2/3 pathways also [26]. TGFβs are also known as both
suppressors and promoters of cancer [29,33].
After posttranslational modifications, TGFβ is secreted
as an inactive complex, known as latent TGFβ, which is
activated by pH changes or proteases [24]. Decorin or
betaglycan binding is reported to be protective against
the protease activation of TGFβ [24]. Since osteoblasts are
known to produce plasminogen activators, they can also
mediate TGFβ production and activation [24]. TGFβ has
high affinity for Alk5, Alk4 and Alk7 throughout type I-R
and binding causes the activation of Smad 2/3 complex
[23, 26, 29, 33] (Figure 5). Activated Smad 2/3 complex
binds to Co-Smad (Smad 4) and is recruited to nucleus.
For maintaining the normal organization of chondrocytes
in growth plate, this Smad 4 mediated TGFβ signaling
is reported to be vital [26]. On the other hand, Smad 7
may inhibit the Wnt activity by binding to β-catenin to
promote Smurf2 mediated ubiquitination of β-catenin for
degradation, which is reported to be an important factor
especially for TGFβ induced β-catenin regulated apoptotic
responses [25].
Because of the complexity of signaling pathways, the
relation of BMP and TGFβ is not totally clarified yet. There
are a few studies [24,33,36] that reported the regulatory
effects of BMP and TGFβ on each other, so that we are able
to know the presence of BMP increases the osteoblast TGFβ
expression as well as TGFβ auto-induced TGFβ expression
in osteoblasts; or TGFβ is known to induce BMP-2
expression in osteoblasts as well as TGFβ-potentiated BMP
osteoinductive activities; and not only osteogenesis related
events but adipogenesis is also reported to be regulated
by the balance between BMP and TGFβ signaling. Both
TGF-β and BMP signal through Smad4 [26]. BMP/TGFβ-activated Smads together with Runx2 forms the skeleton
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Figure 5. Receptor types in BMP and TGFβ signaling. *BMP has weak affinity for ActR II and ActR IIB.
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[26]. TGF-β and BMP synergistically effect ectopic bone
formation [26].
The rational changes in type I and type II receptors
are also thought to have effects on the differentiation
because TGFβ is mentioned to be not capable of binding
type I receptors in the absence of type II receptors; while
the presence of type II receptors they have only an affinity
increasing effect on BMPs [18, 33]. In order to explore
the roles of endogenous TGFβ in osteoblast function in
vivo, Filvaroff et al. [18] truncated type II TGFβR from
the osteocalcin (OCN) promoter to develop a transgenic
mouse in which the osteoblastic responsiveness to
TGFβ is inhibited. They found an altered responsiveness
in cartilage and synovium cells which caused a joint
degeneration similar to human osteoarthritis and an
increase in trabecular volume in femurs of the transgenic
mice by postnatal 35th day and up to months of age the
increase in trabecular volume became more pronounced
compared to wild type mice even after ovariectomy.
They also noted, in transgenic mice the osteocyte density
was far lower than the wild type mice which suggests
that TGFβ signaling is important for normal osteoblast
differentiation in vivo. They concluded that TGFβ has a
direct effect on regulation of bone remodeling, structure
and biomechanical properties via osteoblasts. In another
transgenic mouse study published by Erlebacher et al.
[17], TGFβ2 overexpression was analyzed. Increase in
osteoblastic and osteoclastic activities were observed with
a consequent increase in bone turnover which resulted in
a net imbalance between bone resorption and formation,
concomitantly a progressive, age dependent bone mass.
They also observed mineralization defects in transgenic
mice. Both studies above, done with transgenic mouse
models can be concluded as,
1. Type II TGFβR acts as a dominant negative inhibitor
of TGFβ signaling,
2. TGFβ2 may negatively regulate bone matrix
mineralization in vivo.
The osteoblastic and/or bone regenerative effect of
TGFβ depends on the cell-medium type and the dose/
concentration of the growth factor [40]. Centrella et al.
[40] mentioned the stimulatory effects of TGFβ on the
replication of MSCs in serum free monolayer, however
the effects of TGFβ on mitogenic response of some
cells to other growth parameters were inhibitory. They
also observed the effect of TGFβ on parietal bone cells,
CRL1570 cells and CCL92 cells, with two different doses
of TGFβ (15 ng/mL and 50 ng/mL) and marked the dose
dependent stimulatory effect of TGFβ on DNA synthesis
in confluent cultures of osteoblastic cells while it had
a slight effect on the osteoblast depleted parietal bone
cell cultures [40]. In the same study, it was reported the
collagen synthesis was positively correlated with the TGFβ
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dose while ALP activity was negatively correlated with
TGFβ concentration.
In order to evaluate the enhancement of bone growth
with TGFβ1 in a canine model for 4 weeks, Sumner et
al. [38] spray coated porous titanium rod implants with
HAp (hydroxyapatite) and TCP (tricalcium phosphate)
with different doses of TGFβ (335 µg and 120 µg) and
implanted them bilaterally to the proximal part of the
humerus of each dog with 3 mm gaps between the surface
of the porous coating and the host bone. Although bone
ingrowth was reported to be measured in both groups,
it is mentioned that the amount of bone ingrowth in 120
µg TGFβ1 group was higher than 335 µg TGFβ group
and increasing TGFβ dose caused no significant increase
in bone growth. In another study [41] done with adult
mongrel dogs to observe the dose dependent effects of
rhTGFβ2 with 4 different doses as 0 µg/implant, 1.2 µg/
implant, 12 µg/implant and 120 µg/implant with HAp/
TCP carriers, the implants placed bilaterally in proximal
humeri with 3 mm gaps for 4 weeks. They found the local
application of rhTGFβ2 strongly enhanced bone ingrowth
and gap healing via intramembraneous pathway in a dose
dependent manner. They reported 12 µg rhTGFβ2/implant
dose was more stimulatory than other dose groups, and
excessive doses could be inhibitory by negatively affecting
the osteoid mineralization. Elimelech et al. [37] tested the
different dose effects of TGFβ with βTCP both in vitro
(MSCs with TGFβ doses: 40 ng/mL, 10 ng/mL, 1 ng/mL)
and in vivo (rat calvaria mouse model with TGFβ doses:
40 ng/mL, 0 ng/mL). The results showed that TGFβ1 had
an inhibitory effect on cell proliferation in a dose-time
dependent manner and the maximum inhibition was
seen in 40 ng/mL group after 24 h in vitro while it had no
effect on cell adhesion to βTCP in any of the dose groups.
In vivo, the new bone amount was reported to be almost
same within the 0 ng/mL and 40 ng/mL groups.
2.2. BMP family and its signaling
The largest subset in the TGFβ superfamily is represented
by BMPs which are actively effective in ectopic and
heterotropic bone formation as well as morphogenesis,
bone remodeling, fracture repair, proliferation,
differentiation,
migration,
osteoclastogenesis,
osteogenesis, stem cell commitment, carcinogenesis,
tumor invasion and metastasis, apoptosis, extracellular
matrix remodeling, collagen synthesis, immune functions,
through direct or indirect mechanisms and can act in
endocrine, paracrine and autocrine manner to establish
cell and tissue organization [1,8,20,28,31,32,33,39,42–46].
In vitro BMPs are shown to increase ALP expression in
osteoblasts and bone mesenchymal stromal cells and
to commit MSCs to osteoblastic lineage [24,34,47,48].
Moreover, heterotrophic bone inducing activity is reported
to be related with BMPs and growth differentiation factors

BAL et al. / Turk J Med Sci
(GDFs) rather than TGFβs, activins and several BMPs
and GDFs of TGFβ family [33]. More than 20 BMPs
were defined until now and throughout these BMPs only
BMP1, a metalloproteinase, is known to be a nonmember
of TGFβ superfamily, yet has a role in collagen maturation
as a procollagen C-proteinase and BMP activation as well
as bone and cartilage induction. [33,34,36,45,49,50]. In
addition, BMPs’ osteoinductive activity is reported to be
significantly higher than TGFβ [24].
Contrary to TGFβ, BMPs are not secreted as latent
inactive forms [24] and depending on their amino acid
sequence homology, structures and functions BMP family
can be divided into 4 subclasses as subclass I (BMP2, BMP4), subclass II (BMP5, BMP6, BMP7, BMP8a,
BMP8b), subclass III (BMP9, BMP10), and subclass IV
(BMP12, BMP13, BMP14). However, throughout these
BMPs, only BMP2 to BMP10 (except BMP3 which is an
inhibitor as BMP13) can be classified as bone inducing
BMPs, which can also be divided into 3 subgroups as
Group 1 (BMP-2, BMP4); Group 2 (BMP5-BMP8) and
Group 3 (BMP9, BMP10) depending on their amino acid
homologies [28,34] (Figure 6).
The canonical BMP signaling pathway is reported
to be evolutionarily conserved over at least 700 million
years [28]. In Smad dependent canonical pathway, BMP
regulation occurs from extracellular space through
nucleus via type I and type II receptors, which can be
named as BMP Receptor I (BMPRI) and BMP Receptor
II (BMPRII) in BMP signaling. BMPRII is a specific
receptor only for BMP ligands and however BMP ligands
can also bind to activin receptor (ActR) II and ActR IIB
like activins and myostatins [23,28,33]. Ligand binding
to type II-R activates the Smad 1/5/8 signaling pathway
[22,23,28,29,33]. The activated Smad 1/5/8 makes a
complex with Co-Smad, and is recruited to nucleus.

Group I
BMP2
BMP4

Group II
BMP5
BMP6
BMP7
BMP8a
BMP8b

In nucleus, they associate with either transcriptional
coactivators as p300, CBP, Runx2 and GCN5 or
corepressors as c-Ski, SnoN, Tob and SIP1 and bind to
regulatory elements of the target genes for transcriptional
regulation [28,32,33] (Figure 7). In nucleus, the
interaction with coactivators p300 and CBP are reported
to be important for the transcriptional activity of
phosphorylated R-Smads [33].
Runx2 is a key transcription factor in osteogenesis
and indispensable for bone formation [26,32]. Smad1
is reported to interact with Runx2 on the promoter of
target genes to control osteoblastic gene expression
and differentiation [26]. Li et al. [32] also reported that
although Runx2 has been shown to interact with TGFβspecific Smads (Smad 2 and Smad 3) to block myogenic
differentiation via mimicking the common effects of
TGFβ and BMP-2, it only synergizes with BMP-2, but not
with TGFβ, to induce osteoblastic differentiation.
Depending on the information given above, it is not
hard to see otherwise the Smad 1/5/8 pathway might
be halted without phosphorylation of R-Smads and the
interaction of Smad1/5 with Runx2 – a key transcription
factor in osteogenesis – would be distracted.
Smad 6, as an I-Smad, also takes part in negative
feedback mechanism of BMP signaling and it is required
to limit BMP signaling during endochondral bone
formation and is recruited to cytoplasm from nucleus
via Smurf1 binding; because it is mainly in rest state in
nucleus. Smad 6 binds to Smad 4 to form a nonfunctional
complex in order to halt the binding of Smad 1/5/8 to
Smad4 and inhibits the BMP signaling in bone formation
[26,32]. Chen et al. [26] mentioned about the conditional
deletion of Smad 4 in osteoblasts lead to lower bone
mineral density, bone volume and decreased the bone
formation rate and osteoblast number.

Group III
BMP9
BMP10

Group IV
BMP12
BMP13
BMP14

Figure 6. BMP ligand subfamilies due to their amino acid sequence homology, structure and functions.
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Although BMP is one of the most popular growth factors
which are known as triggering / signaling molecules that
regulate not only growth but also repair and regeneration
[1,21] by promoting osteogenesis, chondrogenesis,
vascularization and formation of fibrotic tissue to
accelerate the maturation progress and callus formation
while inhibiting osteoclastogenesis [8], decreasing blood
loss, surgery time and hospital stay [20,21]; the use of
BMPs is still avoided by many physicians because of
their complications such as an increase incidence in
dysphagia, significant prevertebral swelling, airway edema
compromise [1,2,20,51], uncertain impacts in promoting
tumorigenesis and tumor metastasis [45,52], ectopic bone
formation, osteophyte production [1,20,43,44]. It is also
reported that BMP-2 induces PPARγ activation in a dose
dependent manner and promotes the commitment of
MSCs to adipocyte lineage [20,53]. Thus, it is important to
use BMP in certain amounts with proper delivery vehicles
for dosage control and sustained release and to lengthen
the half-life of the cytokine in body [9,10,54]. For this
purpose, BMPs are used with many natural or synthetic
polymers or composites in the literature (Table).
There are also studies done with metallic megaprostheses for large bone defects however they are reported
to have higher complication rates than conventional
arthroplasty and may require revision surgery due to
infection, loosening and increased wear particles which
may disperse along the joint space in some cases and
can also occupy the adjacent tissues and cause a shift in
homeostasis of bone tissue to osteolysis over time [11,69].
Koolen et al. [19] used commercially available fibrin
as a carrier for BMP-2 in vitro with ATDC5 cells and in a
femur CSD (critical size defect) model in Wistar rats and
observed a burst release of BMP-2 from the constructs
which continued for 28 days with ALP activity in vitro.
In vivo they observed an increase in bone formation with
defect bridging and remodeling without a trace of ectopic
bone formation. Chen et al. [70] also used HLC (human
like collagen) as a carrier for BMP-2 because of its high
affinity for BMPs and its being a natural part of human
bone, in vitro (on SD Rat MSCs with 1 µg BMP) and in
vivo (on Kunming mice as ectopic bone formation model,
and on SD Rats as calvarial defect model with changing

concentrations of BMP as 0 µg, 1 µg, and 5 µg with implant
and without implant). In vitro they reported an increase
in Runx2, Alp and OPN (osteopontin) protein and gene
expressions. In vivo, although no ectopic bone formation
in the absence of HLC implant was observed, the ectopic
bone formation was seen in all groups with BMP + HLC
implants. In rat calvarial defect model, the bone formation
was increased with the increasing doses of BMP, however
in 5 µg BMP + HLC group a significant bone overgrowth
was observed as side effect and 1 µg BMP + HLC group
was reported to be the only effective group with no side
effects. Kaito et al. [2] combined interconnected porous
hydroxyapatite (IP-CHA) and PLA-PEG (polylactic acid
- polyethylene glycol) composites as a carrier system for
different rhBMP-2 doses (0 µg/mL, 5 µg/mL, and 20 µg/
mL) and investigated the bone repair capacity on CSD in
rabbit radius. The results at 8 weeks postoperation showed
5 µg/mL and 20 µg/mL rhBMP-2 groups had almost same
results histologically, biomechanically and radiologically
and they reported a decrease in the required amount of
rhBMP-2 for bone regeneration in rabbit radius CSDs.
The composites or biomaterials that are developed to
provide a sustainable release of BMP or let us say, cytokines,
are of course must be confirmed by the preclinical studies
because in vivo, ex vivo and in vitro effects of the materials
or cytokines most probably will be different. However,
from an ethical point of view, in order to decrease the
number of experimental animals used in preclinical studies
and/or in order to provide more quantified release results,
first these composites or biomaterials should be tested in
vitro for release kinetics and/or cell studies before going
for animal trials to see if the released cytokine amounts
and/or the biomaterials/composites are suitable and if the
release is sustainable and the released cytokines preserve
their activities. To observe the release activity of a cytokine
from the composite there are many methods reported
such as Elisa [71], radiolabeling of the cytokine [72,73],
colorimetric assays as BCA [74]. Depending on the results
of these assays, the cytokine, composite or biomaterial
can or cannot go for other in vitro cell tests and/or animal
experimenting and by using these release kinetic tests the
time-dose dependent results of the cytokine released from
the composite can be obtained and the activity of released
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Figure 7. Transcriptional coactivators and coregulators.
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Table. Carriers of the BMP molecule
Ref.

GF/Material

Experiment model

55

BMP
+
OPF-BP hydrogel with PLGA
microspheres

Rat subcutaneous
implant model

Results
BMP absorbed on the phosphorylated hydrogel
showed better results than the ACS (absorbable
collagen sponge control) group and the bone
formation was 12-fold higher.

Rhesus monkey – L4/L5
laminectomy BLIPA
(Nonhuman primate lumbar
intratransverse process
arthrodesis) model

In control group (AIC-Autologous iliac crest) and
BMP 0 mg group no fusion is observed.
The 6 mg, 9 mg and 12 mg groups showed solid fusion
with 9 mg and 12 mg rhBMP-2 groups resulting in a
formation of quantitatively more and denser bone.
Bone formation in 12 mg groups reported to be not
much than 9mg groups.

BMP-2
+
HA (Hyaluronic Acid)
+
hMSCs

Rat calvarial defect model

Within different combinations of BMP-2-HA-hMSCs,
highest OSN expression and mature bone vascular
markers were observed in HA + hMSCs + BMP-2
group within 4 weeks

IGFβ1/TGFβ1/BMP-2
+
Ti-discs coated with PDLLA

Sheep musculus cleido
mastoideus implantation model

No ectopic bone formation was observed in any groups
Capsule formation was observed only in the GF
(growth factor) loaded side, the GF application
influenced the proliferation of the fibrous tissue.

58

hBMP-2
+
Opencell PLA (OPLA)

Beagle L4-L5 postero-lateral
spinal fusion model
(implantation on transverse
processes)

BMP + OPLA combination was shown to be superior
to AIC.
By 3 months 100% fusion was observed in BMP +
OPLA groups while no fusion was observed in AIC
only groups.

59

rhBMP-2
(96 µg, 48 µg, 0 µg)
+
PLA

Rat nonhealing defect in
mandible

At 13–26 weeks the bone production between 0 µg and
48 µg groups were not significantly different.
although the thickness of the bone was observed in 48
µg group, it decreased in time.
96 µg group showed the most bone formation and the
thickness of the bone tissue was maintained.

60

BMP-2
+
PEG-based hydrogel (OPF.
Oligo PEG fumarate with BPbisphosphonate)

Rat femoral defect model

Phosphate functionalized on BMP-2 surface enhanced
BMP-2 induced ectopic bone formation
Phosphate functional groups enhanced the
osteoconductive characteristics of OPF

61

GF1/BMP-2
+
OPF

Rabbit knee defect model

Combined application of IGF1 + BMP-2 resulted in
better subchondral bone repair than IGF1 group itself.
BMP-2 alone resulted better bone score morphology
Delivery of BMP-2 is thought to accelerate the bone
formation at an early time point.

62

BMP-2
+
Gelatin-βTCP Sponge
+
MSCs

Differentiation of MSCs is enhanced by BMP-2 in vivo
and BMP-2 was retained in sponges more than 4 weeks
Rat subcutaneous implant model
Tissue maturation, increased new bone volume and
ALP, OCN expressions were observed.

56

49

57

rhBMP-2 (0, 6, 9, 12 mg per
side)
+
HA:TCP (60:40)
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Table. (Continued).

63

BMP-2 (0 µg – 0.08 µg
– 8 µg per 1mg of PLGA
microspheres)
+
BMSCs
+
PPF (propylene fumarate)

64

BMP-2
(6 ng, 60 ng)
+
In vitro release profile
Gelatin vs PLGA microparticles experiment
+
PPF scaffolds

BMP-2 release from gelatin microparticles happened
with a minimal burst release and linear release kinetics
afterwards.
PLGA microspheres showed a moderate BMP-2 burst
release followed by a minimal cumulative release
profile.
Addition of collagenase also increased the release of
BMP-2 from the scaffolds

65

rhBMP-2
+
Chitosan (CS) microspheres

Rat muscle bag model

Enhanced ectopic osteogenesis and promoted
osteoblast differentiation by enhancement of ALP
activity and calcium content

BMP-2
(0 µg, 1 µg, 10 µg)
+
Collagen sponge

Increased expression of critical genes were observed to
decrease to their baseline levels after 4 weeks in young
rats while many genes including osteoblastic and
osteoclastic genes, remained upregulated in old rats up
Mid-diaphysis full defect model
to 6 weeks
in old vs young rats
1 µg BMP-2 exhibited prolonged inflammation
compared to 10 µg groups which might be related with
the poor healing of these groups.

66

67

rhBMP-2
(0 µg, 1 µg, 5 µg,
10 µg, 20 µg)
+
Collagen Sponge

68

BMP7
+
PLAGA
[poly(lactide-co-glycolide)]
matrix

Goat ectopic implant model

Rat femoral defect model

Defects with higher doses of rhBMP-2 showed
increased bone bridging in the gap however the
remodeling level was reported to be same for 10 µg and
20 µg groups.
The radiographic score increased with increasing BMP
dose.
However 20 µg group showed lesser healing compared
to 10 µg group

Rabbit skeletal muscle cells

Enhanced synthesis of OCN
Increased calcium and phosphate deposition
Differentiation of skeletal muscle cells to osteoblast like
cell profile

cytokines from the composites can either be tested in vitro,
in vivo or both.
3. Clinical studies
There are also various applications of BMPs and TGFβs in
clinics with carrier molecules [51, 75–84]. However, the
locally applied supraphysiological BMP-2 doses during
surgery is reported to be connected with hematoma
formation in soft tissue, increased inflammatory response,
bone cysts and infection [85] which also increase the
importance of clinical follow-up studies.
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Compared to BMP impregnated scaffolds, microsphere
implantation caused a lower burst release and
sustained over a lone period of time.
No significant effect of BMSC addition before
implantation was reported on the osteoinductive
capacity.

Burkus et al. [82] compared the application of rhBMP-2
with collagen sponge or with autologous iliac crest bone
in a total of 279 patients in 2 years follow up study after
interbody fusion using two tapered threaded Ti-fusion
cages and reported a higher fusion rate in rhBMP-2 with
collagen group.
Since BMP is reported with side effects, Maza et al. [51]
observed the results of small sponge rhBMP-2 application
either within an allograft or a PEEK cage in 47 patients
between 33–74 years of age spectrum within 2010 January
and 2016 November and reported no incidence of expected
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complications such as dyspnea, edema, ectopic bone
formation, or life threatening respiratory events such as
prolonged intubation or complications referred to steroid
usage as delayed healing or diabetes. Sebastian et al. [77]
also aimed to evaluate the safety and efficacy of BMP-2 use
in transforaminal lumbar interbody fusion (TLIF) with
regard to postoperative radiculitis in 77 patients between
18–75 years of age and reported that not only TLIF with
BMP use did not lead to postoperative radiculitis but also
an improvement in back pain was seen in patients.
Similar to preclinical studies, in clinical studies
the dose dependent effects of rhBMP-2 were also
observed. Lytle et al. [78] reported, in the applications of
transforaminal interbody fusion between the years 2009 to
2014, there observed an increase in fusion odds as BMP
dose increased from 0.16–1.0 mg/level to 1.0–2.0 mg/level
while no increase in fusion odds was observed when BMP
dose was more than 2.0 mg/level and reported that 1.0 mg/
level was the minimally effective dose and concluded that
as the BMP dose/level is a significant precursor of fusion.
Govender et al. [75] also reported a 20 months follow up
study of an open tibial fracture case of 450 patients with
study groups of standard care (SC–intramedullary nail
fixation and routine soft tissue management), SC + implant
(absorbable collagen) coated with 0.75 µg/mL rhBMP-2
and SC + implant coated with 1.50 µg/mL rhBMP-2.
They observed a 44% decrease in the risk of failure, and
increase in fracture healing time and wound healing time
in SC + implant coated with 1.50 µg/mL rhBMP-2 group
compared to SC.
These results may show us that, the required dose of
BMP-2 also depends on the application place, the surgical
procedure as well as the implant type.
4. Perspective
Pseudo-arthrosis which may result from complete
fractures, huge bone gaps as a result of tumor resection,
need for the large amount of trabecular bone for spinal
fusion surgeries, osteonecrosis as well as impaired bone
healing are the main problems in orthopaedics [86,87].
In clinics, open fractures, tumor resection, insufficient
immobilization, inadequacy or lack of blood supply, poor
nutrition or the effect of other metabolic diseases such as
diabetes, may cause delayed healing or nonunion or the
decrease in bone mineral density with age and osteopenia
and/or osteoporosis may cause fracture, nonintegration
of the material/instrument or collapse of the surgical
procedure and/or composite [1,11,86,88,89]. Lee et al. [90]
reported the need for bone grafting is between 0.5–1.5
million per year in the USA alone and half of them are for
spinal fusion surgeries yet the pseudo-arthrosis is reported
to be 5%–43% for posterolateral spinal grafting [90]. Also,
the delayed healing rate was reported to be in the range of

16%–60% for less severe fractures and 43%–10% for more
severe fractures and the nonunion rate is reported to be
4%–10% [89]. In addition to postoperative problems or
complications, the economic side of these surgeries and
instrumentations as well as composites is another problem
that we have to face in clinic [79,91].
It is well known that for the integration of the
material the osteoinductivity, osteoconductivity and
osteogenic activity are important. However, in patients
with osteoporosis, the increased bone remodeling and
the negative final bone balance based upon the decreased
osteoinductive, osteoconductive and osteogenic capacities
of the bone, becomes one of the main problems related
with the poor bone fusion [88]. Diaz-Romero Paz et al.
[88] mentioned the other scoliotic deformities are also
seen in high percentages as 36%–48% in women with
osteoporosis and spinal surgery complications are mostly
seen in patients aged over 65 or with osteoporosis. In spinal
fusion, the instruments used, such as screws or nails, as
well as the bone that they are inserted in are exposed to
body fluids and stress, which may increase their corrosion.
The bone area around the implant will be affected by this
corrosion effect and especially in cases with decreased
bone mineral density (BMD) as it is seen in osteoporosis,
this damage in and around the implant will be drastic. The
pullout or removal of the pedicle screws are reported to
be one of the most seen complications within 3 months
after spinal surgery [88]. Hence, a suitable material that
can contribute an increase in the BMD values at the
area of application of instruments while providing bone
formation concurrently, seems essential in spinal or other
orthopedic applications.
Bone growth factors are the cytokines that naturally
take part in development processes as well as new
bone formation, fracture healing, proliferation and
differentiation [20,45,90]. Throughout them, TGFβ
superfamily as previously mentioned is one of the most
popular because of its effects on bone. Within this family,
BMPs as cytokines with the highest osteogenic properties,
are the ones which are studied widely in bone regeneration
applications as well as in clinic and within them, rhBMP-2
is reported to be the first BMP that was introduced as a
bone graft substitute [20]. After the approval of its use in
clinics, the use of rhBMP-2, especially in spine surgeries,
increased drastically because its use decreased blood loss
and surgical time and increased fusion rates [1,21,81].
However, the increased use of rhBMP-2 also brought the
negative side effects depending on the high dose usage
are also mentioned in this article previously, since they
are already pleiotropic [43], yet these are not the only
problems related with BMPs. Solubility of BMP is also one
of the major problems to be overcome before the clinical
applications [46,54] because the fast release of BMP will
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result in the loss of the cytokine in the application area and
will decrease the regenerative effect of it. Nevertheless,
these complications did not prevent the use of these
cytokines in the clinics because the clinical studies showed
better results with BMP-2 than autogenous bone grafting
alone [20,92]. The advantage of increased rate in spinal
fusion with the combination of BMPs [20,56,76,78,79,91]
and BMPs’ having high capacity for bone regeneration and
capability of fracture healing keep them popular in bone
regeneration studies and make them a popular research
area also in basic science in order to find suitable carriers
for these cytokines to be released in a sustained manner
with a decrease in required dose for bone regeneration.
Thus, it is an important research area to find new materials
to fill bone defects and/or to support the instruments
that are used to stabilize the bone while supporting bone
regeneration and the sustained release of the cytokine
and/or to understand the signaling pathways of cytokines,
how they work in cellular level on differentiation and
proliferation in order to prevent the probable progression
of a disease before it needs a replacement surgery.
In addition, the dual effects of both TGFβ and BMPs
necessitate the better understanding of the molecular
pathways of the growth factors that are going to be used
in bone regeneration studies. As an example, TGFβ is
known to be related with not only bone formation but
also tumorigenesis and in tumorigenesis it is reported to
have a dual role as a tumor suppressor in early stages of
carcinogenesis and as a promoter of tumor metastases in
advanced stages of carcinogenesis [93]. In addition since
TGFβ, as mentioned before, has pleiotropic effects, it is
not only related with bone but its activity is also observed
in ovarian, pancreatic, colon cancers and in squamous cell
carcinoma and is reported that the over activity causes
Camurati-Engelmann disease of bone, which occurs
because of a missense mutation in the latency associated
peptide that causes a constitutively active TGFβ [94].
Similarly, a gain of function mutation in Alk-2, as one of the
BMPRI, causes fibrodysplasia ossificans progressiva (FOP)
[33]. Previously in this paper, BMPs’ and TGFβs’ probable
effects on EMT were also mentioned. Although in this
paper mostly Smad pathways are mentioned, for TGFβ to
induce the EMT a cooperation between Ras/MAPK and
TGFβ/Smad pathways is required [93] which shows us
the complicated relation between signaling pathways of
molecules should to be studied and understood further
not only for the successful and suitable applications of
cytokines with no or low side effects for bone regeneration
but also for the treatment or prevention of the genetic
bone diseases related with these cytokines.
5. Conclusion
Proteins in TGFβ super family are all growth and
differentiation factors that take role in organogenesis,
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tissue remodeling and survival [45]. BMP is one of the
biggest subfamilies of TGFβ superfamily and more than
20 human BMPs are described until now [20,45]. They are
known to take part in bone formation, cell proliferation,
migration and survival [23,34]. It is also mentioned that
Klf4 as one of the factors with Oct4, Sox2, and c-Myc, which
are important for redifferentiation of mouse embryonic
fibroblasts to mouse ES-like stem cells (iPS Cells) and can
be replaced by BMPs which is a proof of their influence in
MET (mesenchymal epithelial transition) and shows their
significant roles in the maintenance and differentiation of
pluripotent stem cells [33].
Despite their positive effects on bone regeneration,
the complications restrict the use of these growth factors.
The most common adverse effect of BMP-2 use is defined
as ectopic bone formation [20], however they are also
implicated in triggering epithelial phenotypic changes
that cause them become more similar to mesenchymal
cells [45], which increases the probability of epithelial
mesenchymal transition – a cause of metastatic potential in
oncogenic EMT. Similarly, TGFβ activation is shown to be
activated in an EMT related Snail1 gene and resulted in the
repression of the transcription of e-cadherine gene [28].
In basic biological studies, upregulation of BMP ligand
expression has been shown in various carcinomas, and
also they have been mentioned to increase the invasiveness
of prostate, lung, oral SCC and breast carcinoma as well
as the proliferation within multiple carcinoma types [20].
Katagiri et al. [33] reported TGFβ and BMP are both
suppressors and promoters of cancer and mentioned the
importance of autocrine TGFβs in maintenance of stem
cell like properties and tumorogenic activity of glioma
initiating cells (GICs) and the effects of BMP signals on
induction of differentiation of GICs. Yet, there are other
studies emphasizing the increased expression of BMPRII
has a suppressive role in tumors [95] which brings us to
the result that the effects of BMP on tumor formation or
carcinogenesis should be dose dependent.
BMPs and TGFβ take part in bone homeostasis and
regeneration together, however the relation between TGFβ
itself and BMP on bone regeneration process has not been
clearly understood yet. Asparuhova et al. [96] analyzed
the TGFβ and BMP-2 protein release from mesenchymal
stromal cell line ST2 on deproteinized bovine bone
mineral (DBBM) and collagen membranes precoated with
bone conditioned medium (BCM). BCM was reported
to induce enhanced proliferation of TGFβ1 and BMP-2
specific R-Smads and TGFβ showed faster release kinetics
than BMP-2. They also examined TGFβ1 effect on BMP
with various concentrations of TGFβ1-only or various
concentrations of TGFβ1 combined with certain dose of
BMP-2. In all groups BMP alone was shown to upregulate
the expression of all osteoblast specific mRNAs. TGFβ1
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effect was also reported to increase the Colα1, Colα2
and Spp1 mRNAs while it slightly decreased the mRNA
expressions of Runx2, Bglap2, Ibsp, and Alp1 in a dose
dependent manner so they concluded that TGFβ1 exhibits
a stimulatory and dose dependent effect on BMP-2
induced osteoblast differentiation. The mineralization was
reported to be stimulated with BMP-2 but not TGFβ1,
however TGFβ1 was shown to enhance BMP-2 induced
deposition of mineralized matrix by ST2 cells significantly.
They also proved the stimulation in Smad1/5/8 pathways
was seen 24 h after BMP-2 introduction although the
levels of Smad1/5/8 was decreased after 2 h. However,
with combination of TGFβ1 and BMP-2, Smad1/5/8
pathway was also stimulated and the expression was
prolonged compared to BMP-2-only introduction. It was
also reported that the presence of BMP increased the
osteoblastic TGFβ expression or vice versa and TGFβ was
shown to potentiate the osteoinductive activities of BMPs

which suggested a positive feedback mechanism between
these two growth factors [24].
For cytokines with pleiotropic effects and complicated
signaling pathway relations which have not been
understood completely yet, the use in clinics will also
bring the complications regardless of the positive effects
on bone or cartilage regeneration. For growth factors to be
effective, the cytokines should be kept in the implantation
site to ensure they will be able to exert their biological
actions [9]. To provide this, the development of new
biomaterials which are proper not only as carriers for
sustainable release of cytokines but also as cell substrates,
nutrient suppliers, or mechanical supports is as important
as the study of signaling pathways between cytokines and/
or related diseases.
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